Praxis Precision Medicines
PRAX
108 hedge funds and large institutions have $95.6M invested in Praxis Precision Medicines in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
14% more funds holding
Funds holding: 95 → 108 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.15% less ownership
Funds ownership: 6.32% → 6.16% (-0.15%)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
9% less capital invested
Capital invested by funds: $106M → $95.6M (-$9.9M)
Top Buyers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.27M |
| 2 |
Millennium Management
New York
|
+$2.34M |
| 3 |
Goldman Sachs
New York
|
+$1.75M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.66M |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
+$1.38M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.45M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.19M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$959K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$925K |
PRAX Hedge Fund Activity: Q3 2022 in Review
108 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2022, worth a combined $95.6M — down 9.4% from $106M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PRAX positions and 13 closed out — a net gain of 13 holders — while 29 added to existing stakes and 31 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $4.27M. The largest seller was State Street, cutting an estimated $14M.
- 108 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2022, up from 95 in Q2 2022.
- Funds reported $95.6M of Praxis Precision Medicines stock for Q3 2022, down 9.4% quarter-over-quarter.
- 26 funds opened new Praxis Precision Medicines positions in Q3 2022 and 13 closed out, a net change of +13 holders.
- The largest Praxis Precision Medicines buyer in Q3 2022 was EcoR1 Capital, an estimated $4.27M added.
- The largest Praxis Precision Medicines seller in Q3 2022 was State Street, an estimated $14M sold.
Based on aggregated 13F filings for Q3 2022.